KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to $41.0 million.

  • Rigel Pharmaceuticals' Operating Expenses fell 50.67% to $41.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $163.1 million, marking a year-over-year increase of 1024.12%. This contributed to the annual value of $155.1 million for FY2024, which is 1289.41% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Operating Expenses stood at $41.0 million, which was down 50.67% from $40.6 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Operating Expenses ranged from a high of $49.2 million in Q4 2022 and a low of $32.2 million during Q2 2023
  • For the 5-year period, Rigel Pharmaceuticals' Operating Expenses averaged around $39.6 million, with its median value being $40.6 million (2025).
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 2846.75% in 2021, then tumbled by 3124.66% in 2023.
  • Rigel Pharmaceuticals' Operating Expenses (Quarter) stood at $41.8 million in 2021, then grew by 17.62% to $49.2 million in 2022, then tumbled by 31.25% to $33.8 million in 2023, then rose by 21.03% to $40.9 million in 2024, then increased by 0.25% to $41.0 million in 2025.
  • Its Operating Expenses stands at $41.0 million for Q3 2025, versus $40.6 million for Q2 2025 and $40.6 million for Q1 2025.